External Quality Assurance of HER2 FISH and ISH Testing Three Years of the UK National External Quality Assurance Scheme

被引:27
作者
Bartlett, John M. S. [1 ,2 ]
Ibrahim, Merdol [2 ]
Jasani, Bharat [4 ]
Morgan, John M. [4 ]
Ellis, Ian [5 ]
Kay, Elaine [6 ,7 ]
Connolly, Yvonne [8 ]
Campbell, Fiona [1 ]
O'Grady, Anthony
Barnett, Sarah [3 ]
Miller, Keith [2 ]
机构
[1] Western Gen Hosp, Edinburgh Canc Res Ctr, Endocrine Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland
[2] UK Natl External Qual Assessment Serv, London, England
[3] UCL, London, England
[4] Cardiff Univ, Sch Med, Dept Pathol, Cardiff, S Glam, Wales
[5] Univ Nottingham, Dept Histopathol, City Hosp Nottingham, Nottingham NG7 2RD, England
[6] Beaumont Hosp, Dept Histopathol, Dublin 9, Ireland
[7] Beaumont Hosp, Royal Coll Surg Ireland, Dublin 9, Ireland
[8] Natl Childrens Hosp, Adelaide & Meath Hosp, Dublin, Ireland
关键词
HER2; Fluorescence in situ hybridization; In situ hybridization; Quality assurance; Practice guidelines; Gene/chromosome ratio; Gene copy number; TRANSITIONAL-CELL CARCINOMA; METASTATIC BREAST-CANCER; SITU HYBRIDIZATION FISH; AMPLIFICATION; TRASTUZUMAB; RECOMMENDATIONS; CHEMOTHERAPY; SENSITIVITY; RECURRENCE; ANEUSOMY;
D O I
10.1309/AJCPLN78ZQXEMNMA
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The American Society of Clinical Oncology/College of American Pathologists guidelines highlighted the critical importance of quality assurance in diagnostic testing for HER2. Unstained formalin-fixed, paraffin-embedded human breast carcinoma cell line sections were circulated to scheme participants on 9 occasions. "Reference laboratories" reported results for the HER2/chromosome 17 ratio and HER2 copy number for 3 years for each cell line, including 418 sets of results (1,671 results total). The number of participants was 62 laboratories in the final analysis. The mean and SD of results from reference laboratories demonstrated consistency during by the 3-year period The percentage of laboratories achieving "appropriate" results ranged from 45% to 88%, and the percentage achieving "inappropriate" results ranged from 5% to 29%. No consistent effect of the HER2 in situ hybridization testing method was demonstrated. Participation in external quality assurance schemes is a valuable mechanism for demonstrating and acquiring consistency for HER2 testing by in situ hybridization. Poor performance can be corrected via assistance and advice.
引用
收藏
页码:106 / 111
页数:6
相关论文
共 24 条
  • [1] The clinical evaluation of HER-2 status: which test to use?
    Bartlett, J
    Mallon, E
    Cooke, T
    [J]. JOURNAL OF PATHOLOGY, 2003, 199 (04) : 411 - 417
  • [2] Bartlett JMS, 1997, J PATHOL, V182, pA20
  • [3] Pharmacodiagnostic testing in breast cancer - Focus on HER2 and trastuzumab therapy
    Bartlett, JMS
    [J]. AMERICAN JOURNAL OF PHARMACOGENOMICS, 2005, 5 (05) : 303 - 315
  • [4] Evaluating HER2 amplification and overexpression in breast cancer
    Bartlett, JMS
    Going, JJ
    Mallon, EA
    Watters, AD
    Reeves, JR
    Stanton, P
    Richmond, J
    Donald, B
    Ferrier, R
    Cooke, TG
    [J]. JOURNAL OF PATHOLOGY, 2001, 195 (04) : 422 - 428
  • [5] External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme
    Bartlett, John M. S.
    Ibrahim, Merdol
    Jasani, Bharat
    Morgan, John M.
    Ellis, Ian
    Kay, Elaine
    Magee, Hilary
    Barnett, Sarah
    Miller, Keith
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (07) : 816 - 819
  • [6] Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    Dowsett, M
    Bartlett, J
    Ellis, IO
    Salter, J
    Hills, M
    Mallon, E
    Watters, AD
    Cooke, T
    Paish, C
    Wencyk, PM
    Pinder, SE
    [J]. JOURNAL OF PATHOLOGY, 2003, 199 (04) : 418 - 423
  • [7] Standardization of HER2 testing:: results of an international proficiency-testing ring study
    Dowsett, Mitch
    Hanna, Wedad M.
    Kockx, Mark
    Penault-Llorca, Frederique
    Rueschoff, Josef
    Gutjahr, Thorsten
    Habben, Kai
    van de Vijver, Marc J.
    [J]. MODERN PATHOLOGY, 2007, 20 (05) : 584 - 591
  • [8] Recommendations for HER2 testing in the UK
    Ellis, IO
    Dowsett, M
    Bartlett, J
    Walker, R
    Cooke, T
    Gullick, W
    Gusterson, B
    Mallon, E
    Lee, PB
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (12) : 890 - 892
  • [9] Updated recommendations for HER2 testing in the UK
    Ellis, IO
    Bartlett, J
    Dowsett, M
    Humphreys, S
    Jasani, B
    Miller, K
    Pinder, SE
    Rhodes, A
    Walker, R
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (03) : 233 - 237
  • [10] Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization
    Isola, J
    Tanner, M
    Forsyth, A
    Cooke, TG
    Watters, AD
    Bartlett, JMS
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (14) : 4793 - 4798